Chronic rejection inhibitor
View Patent ↗The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.
1. A method for suppressing chronic rejection reaction, which comprises administering a composition comprising an antibody that recognizes an IL-6 receptor to a subject in need thereof prior to organ transplantation, at the time of organ transplantation, or after organ transplantation, thereby suppressing chronic rejection reaction in the subject with a transplanted organ after the organ transplantation, wherein the antibody that recognizes an IL-6 receptor is the only active ingredient in the composition.
2. The method of claim 1 , wherein the antibody is a monoclonal antibody.
3. The method of claim 1 , wherein the antibody is an antibody that recognizes a human IL-6 receptor.
4. The method of claim 1 , wherein the antibody is a recombinant antibody.
5. The method of claim 1 , wherein the antibody is a chimeric, humanized, or human antibody.
6. The method of claim 1 , which suppresses chronic rejection reaction in heart transplantation.
7. A method of suppressing chronic rejection reaction, which comprises administering an antibody that recognizes an IL-6 receptor to a subject in need thereof prior to organ transplantation, at the time of organ transplantation, or after organ transplantation, thereby suppressing chronic rejection reaction in the subject with a transplanted organ after the organ transplantation, wherein the antibody that recognizes an IL-6 receptor is the only antibody administered.
8. The method of claim 1 , wherein the active ingredient suppresses chronic rejection reaction.